400 related articles for article (PubMed ID: 10786814)
1. Immunoreactivity of MIC2 (CD99) in acute myelogenous leukemia and related diseases.
Zhang PJ; Barcos M; Stewart CC; Block AW; Sait S; Brooks JJ
Mod Pathol; 2000 Apr; 13(4):452-8. PubMed ID: 10786814
[TBL] [Abstract][Full Text] [Related]
2. Immunoreactivity of MIC2 (CD99) and terminal deoxynucleotidyl transferase in bone marrow clot and core specimens of acute myeloid leukemias and myelodysplastic syndromes.
Kang LC; Dunphy CH
Arch Pathol Lab Med; 2006 Feb; 130(2):153-7. PubMed ID: 16454553
[TBL] [Abstract][Full Text] [Related]
3. MIC2 detection in tumors of bone and adjacent soft tissues.
Devaney K; Abbondanzo SL; Shekitka KM; Wolov RB; Sweet DE
Clin Orthop Relat Res; 1995 Jan; (310):176-87. PubMed ID: 7641436
[TBL] [Abstract][Full Text] [Related]
4. 013 (CD99) positivity in hematologic proliferations correlates with TdT positivity.
Robertson PB; Neiman RS; Worapongpaiboon S; John K; Orazi A
Mod Pathol; 1997 Apr; 10(4):277-82. PubMed ID: 9110287
[TBL] [Abstract][Full Text] [Related]
5. CD117/CD34 expression in leukemic blasts.
Wells SJ; Bray RA; Stempora LL; Farhi DC
Am J Clin Pathol; 1996 Aug; 106(2):192-5. PubMed ID: 8712172
[TBL] [Abstract][Full Text] [Related]
6. MIC2 analysis in pediatric lymphomas and leukemias.
Riopel M; Dickman PS; Link MP; Perlman EJ
Hum Pathol; 1994 Apr; 25(4):396-9. PubMed ID: 8163272
[TBL] [Abstract][Full Text] [Related]
7. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
8. CD99 (p30/32MIC2) immunoreactivity in the diagnosis of leukemia cutis.
Dorfman DM; Kraus M; Perez-Atayde AR; Barnhill RL; Pinkus GS; Granter SR
Mod Pathol; 1997 Apr; 10(4):283-8. PubMed ID: 9110288
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia with t(6;9) (p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype.
Alsabeh R; Brynes RK; Slovak ML; Arber DA
Am J Clin Pathol; 1997 Apr; 107(4):430-7. PubMed ID: 9124211
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia. Correlation between VEGF expression and the FAB category.
Ghannadan M; Wimazal F; Simonitsch I; Sperr WR; Mayerhofer M; Sillaber C; Hauswirth AW; Gadner H; Chott A; Horny HP; Lechner K; Valent P
Am J Clin Pathol; 2003 May; 119(5):663-71. PubMed ID: 12760284
[TBL] [Abstract][Full Text] [Related]
11. Olfactory neuroblastoma and other round cell lesions of the sinonasal region.
Devaney K; Wenig BM; Abbondanzo SL
Mod Pathol; 1996 Jun; 9(6):658-63. PubMed ID: 8782204
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
[TBL] [Abstract][Full Text] [Related]
13. Induction of death (CD95/FAS), activation and adhesion (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-alpha and IFN-gamma.
Munker R; Andreeff M
Cytokines Mol Ther; 1996 Sep; 2(3):147-59. PubMed ID: 9384699
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia.
Porwit-MacDonald A; Ivory K; Wilkinson S; Wheatley K; Wong L; Janossy G
Leukemia; 1995 Jul; 9(7):1191-8. PubMed ID: 7543174
[TBL] [Abstract][Full Text] [Related]
15. Detection of residual disease in AML patients by use of double immunological marker analysis for terminal deoxynucleotidyl transferase and myeloid markers.
Adriaansen HJ; Jacobs BC; Kappers-Klunne MC; Hählen K; Hooijkaas H; van Dongen JJ
Leukemia; 1993 Mar; 7(3):472-81. PubMed ID: 7680403
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis.
Terstappen LW; Safford M; Könemann S; Loken MR; Zurlutter K; Büchner T; Hiddemann W; Wörmann B
Leukemia; 1992 Jan; 6(1):70-80. PubMed ID: 1540262
[TBL] [Abstract][Full Text] [Related]
17. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML).
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Kroell T; Pfister K; Schmetzer H
Ann Hematol; 2005 May; 84(5):287-97. PubMed ID: 15592672
[TBL] [Abstract][Full Text] [Related]
18. Frequent p53 overexpression in therapy related myelodysplastic syndromes and acute myeloid leukemias: an immunohistochemical study of bone marrow biopsies.
Orazi A; Cattoretti G; Heerema NA; Sozzi G; John K; Neiman RS
Mod Pathol; 1993 Sep; 6(5):521-5. PubMed ID: 8248107
[TBL] [Abstract][Full Text] [Related]
19. Granulocytic sarcoma masquerading as Ewing's sarcoma: a diagnostic dilemma.
Haresh KP; Joshi N; Gupta C; Prabhakar R; Sharma DN; Julka PK; Rath GK
J Cancer Res Ther; 2008; 4(3):137-9. PubMed ID: 18923208
[TBL] [Abstract][Full Text] [Related]
20. Aberration antigen expression in adult acute myelocytic leukemias.
Chen SS; Zhang HF; Xue WT; Li K; Fu JF; Wang DB; Wu PN
Chin Med J (Engl); 1993 Jun; 106(6):419-22. PubMed ID: 8222892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
